
Researchers at the University of Buffalo used combined middle-up and bottom-up LC–MS/MS to characterize the HIV-1 broadly neutralizing antibody PGT 121. They identified multiple Fc and site-specific glycoforms and an unexpected N-terminal serine, revealing significant structural heterogeneity. This integrated approach enhances understanding of bNAb structure, supporting quality control and clinical development. LCGC International spoke to Troy Wood, corresponding author of the paper resulting from this research.






























